Vascular BioSciences Announces Publication of “Intratracheally Administered Peptide-Modified Lipid Admixture Containing Fasudil and/or DETA NONOate Ameliorates Various Pathologies of Pulmonary Arterial Hypertension”
Vascular BioSciences Announces Publication of Promising Preclinical Results for Novel Inhaled Targeted Therapy for Pulmonary Arterial Hypertension in the current Issue of the medical journal Pharmaceuticals
Goleta, CA, March 12, 2024 – Vascular BioSciences announces the recent publication of “Intratracheally Administered Peptide-Modified Lipid Admixture Containing Fasudil and/or DETA NONOate Ameliorates Various Pathologies of Pulmonary Arterial Hypertension” in the latest issue of Pharmaceuticals (Volume 16, November 28, 2023) by Tanoy Sarkar, Sakib M. Moinuddin, Ayman Isbatan, Jiwang Chen, David Mann, and Fakhrul Ahsan. This article details an innovative approach to treating pulmonary arterial hypertension (PAH) by using liposomal formulations of two investigational drugs: fasudil, a Rho-kinase inhibitor, and DETA NONOate (DN), a nitric oxide donor. This novel treatment involves a combination therapy of these drugs delivered in PAH-homing CAR liposomes.
Pulmonary arterial hypertension is a significant, yet often overlooked health issue that affects hundreds of thousands of individuals. The therapeutic strategies available often provide temporary symptomatic relief but introduces potential health risks or fails to offer a definitive cure. These limitations underscore the necessity for the exploration of alternative therapeutic solutions. This research describes a promising strategy using CAR-lipid targeted liposomes containing fasudil, DN, or a combination of both for PAH treatment. The study demonstrated a remarkable 50% reduction in mPAP and RVSP, along with similar improvements in right heart remodeling and echocardiographic parameters compared to untreated PAH animals. In addition, reductions in pulmonary artery muscularization and collagen deposition were also observed. These findings highlight the potential of fasudil, DN and their combination in a CAR-homing peptide targeted liposomes to improve pulmonary hemodynamics, RV functions, and pathological alterations in the pulmonary vasculature. These treatments appeared safe at doses that were pharmacologically effective.
Dr. Fakhrul Ahsan, Distinguished Professor at California Northstate University College of Pharmacy and corresponding author, described the importance of the findings. “This study highlights the significant therapeutic benefits of using fasudil and DN in CAR-targeted liposomes in a preclinical model of severe PAH,” stated Dr. Ahsan.
Vascular BioSciences CEO and study co-author David Mann highlighted the remarkable nature of the findings, “Unlike other experiments that test therapies when administered prophylactically, this remarkable reversal of PAH pathologies was obtained under the challenging condition of already established severe disease.”
A copy of this article can be found here:
About Vascular BioSciences
Vascular BioSciences, a diversified biomedical company with operations in California and North Carolina, provides targeted solutions for serious diseases in order to enhance and prolong human life.
Vascular BioSciences makes interventional catheters to obtain endoarterial biopsies, provides molecular diagnostic services, and through its majority owned subsidiary VBS Pharmaceuticals, develops targeted therapeutics for patients with difficult-to-treat diseases.
More information about VBS is available at http://www.vascularbiosciences.com/
For more information, please contact dmann@vascularbiosciences.com